(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 April 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first three months of 2016. OPERATING HIGHLIGHTS Excellent Opsumit (macitentan) trajectory sustained Outstanding early US launch momentum for Uptravi(selexipag) Significant recruitment drive into Phase III programs 3 New compounds delivered from Drug Discovery to the clinic FINANCIAL HIGHLIGHTS Product sales of CHF 589 million (+11% at CER) Opsumit sales grow to CHF 178 million Uptravi sales of CHF 35 million - enhanced by launch inventory Core operating income of CHF 249 million (+8% at CER) 2016 financial guidance upgrade: High single-digit percentage core...
↧